Shares of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) saw an uptick in trading volume on Tuesday . 11,193,437 shares were traded during trading, an increase of 25,486% from the previous session’s volume of 43,748 shares.The stock last traded at $5.65 and had previously closed at $4.20.
Several brokerages recently issued reports on ALDX. ValuEngine lowered shares of Aldeyra Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, September 6th. Canaccord Genuity set a $12.00 price target on shares of Aldeyra Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, June 14th. HC Wainwright set a $18.00 price target on shares of Aldeyra Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Zacks Investment Research lowered shares of Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 17th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $16.00 target price on shares of Aldeyra Therapeutics in a report on Wednesday, May 31st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. Aldeyra Therapeutics presently has an average rating of “Buy” and an average target price of $14.15.
The stock’s market cap is $35.28 million. The firm’s 50 day moving average is $4.38 and its 200 day moving average is $4.66.
Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.35) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.02. On average, analysts expect that Aldeyra Therapeutics, Inc. will post ($1.63) EPS for the current year.
In related news, major shareholder Life Sciences Maste Perceptive bought 296,007 shares of the firm’s stock in a transaction that occurred on Friday, June 30th. The shares were acquired at an average cost of $4.60 per share, for a total transaction of $1,361,632.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 28.40% of the company’s stock.
Several hedge funds have recently modified their holdings of ALDX. Sphera Funds Management LTD. grew its stake in Aldeyra Therapeutics by 81.4% in the first quarter. Sphera Funds Management LTD. now owns 668,500 shares of the biotechnology company’s stock valued at $3,343,000 after purchasing an additional 300,000 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Aldeyra Therapeutics in the first quarter valued at about $132,000. Sabby Management LLC purchased a new position in Aldeyra Therapeutics in the first quarter valued at about $898,000. Perceptive Advisors LLC grew its stake in Aldeyra Therapeutics by 48.7% in the first quarter. Perceptive Advisors LLC now owns 2,885,458 shares of the biotechnology company’s stock valued at $12,897,000 after purchasing an additional 945,000 shares in the last quarter. Finally, Hikari Power Ltd grew its stake in Aldeyra Therapeutics by 186.4% in the second quarter. Hikari Power Ltd now owns 107,858 shares of the biotechnology company’s stock valued at $507,000 after purchasing an additional 70,196 shares in the last quarter. Institutional investors and hedge funds own 49.09% of the company’s stock.
WARNING: This news story was posted by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/2887301/aldeyra-therapeutics-inc-aldx-sees-large-volume-increase.html.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.